BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.

The settlement payment of $467 million related to a contractual dispute with the University of Pennsylvania is expected to be reflected in the Company's second quarter 2025 financial results. In ...

Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel. BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties BioNTech has entered into two separate ...

DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of ...

BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was down 19.5% compared to the same quarter last year. During the same period last year ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key biopharma sector uncertainty but major economic worries ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioNTech reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year. The company ...